• Molecular NameImipenem
  • SynonymImipemide; Imipenem, n-formimidoyl thienamycin; IMP; N-formimidoylthienamycin
  • Weight299.351
  • Drugbank_IDDB01598
  • ACS_NO74431-23-5
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.22
  • pkaN/A
  • LogD (pH=7, predicted)-2.28
  • Solubility (experiment)10 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.77
  • LogSw (predicted, AB/LogsW2.0)2.01
  • Sw (mg/ml) (predicted, ACD/Labs)50.67
  • No.of HBond Donors4
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds6
  • TPSA141.52
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn intravenous β-lactam antibiotic developed in 1985. It has an extremely broad spectrum of activity.
  • Absorption_value5.0
  • Absorption (description)When compared to intravenous administration of imipenem-cilastatin sodium, imipenem is approximately 75% bioavailable following intramuscular administration while cilastatin is approximately 95% bioavailable. The absorption of imipenem from the IM injection site continues for 6 to 8 hours while that for cilastatin is essentially complete within 4 hour
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding20.0
  • Volume of distribution (VD)0.23 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmImipenem, when administered alone, is metabolized in the kidneys by dehydropeptidase I resulting in relatively low levels in urine. Cilastatin sodium, an inhibitor of this enzyme, effectively prevents renal metabolism of imipenem so that when imipenem and cilastatin sodium are given concomitantly, fully adequate antibacterial levels of imipenem are achieved in the urine
  • Half life0.9 h
  • ExcretionRenal
  • Urinary Excretion69
  • Clerance2.9 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A